{"title":"口服锌对血液透析患者血红蛋白和促红细胞生成素剂量的影响。","authors":"Shiva Seirafian, Awat Feizi, Shahrzad Shahidi, Shirin Sadat Badri, Mohammad Hossein Rouhani, Pejman Pourazari Najafabadi, Elham Kabiri Naeini","doi":"10.4103/jrms.jrms_271_23","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In hemodialysis (HD) patients, low serum zinc level could cause hyporesponsivity to erythropoiesis-stimulating agents and lead to anemia. This study investigated the effects of oral zinc supplements on the required dose of erythropoietin in patients undergoing HD.</p><p><strong>Materials and methods: </strong>In a double-blinded randomized trial, 76 HD patients were assigned to 2 groups of 38. One group (intervention) was treated with oral zinc supplements of 210 mg, daily for 6 months, and the other group (control) used placebo capsules for 6 months. The serum zinc level, hemoglobin level, and required dose of erythropoietin, albumin, ferritin, ferrous, and total iron-binding capacity were evaluated 3 and 6 months after intervention.</p><p><strong>Results: </strong>Repeated measures ANOVA did not show a significant increase in Hb level after 6 months of intervention (<i>P</i> = 0.28). However, the required dose of erythropoietin was decreased, but the changes were not statistically significant (<i>P</i> > 0.05). The changes in the other variables were not statistically significant.</p><p><strong>Conclusion: </strong>Oral zinc supplementation in HD patients could not increase hemoglobin level irrespective of their serum zinc level.</p>","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"28 ","pages":"85"},"PeriodicalIF":1.5000,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10953733/pdf/","citationCount":"0","resultStr":"{\"title\":\"The effect of oral zinc on hemoglobin and dose of erythropoietin in hemodialysis patients.\",\"authors\":\"Shiva Seirafian, Awat Feizi, Shahrzad Shahidi, Shirin Sadat Badri, Mohammad Hossein Rouhani, Pejman Pourazari Najafabadi, Elham Kabiri Naeini\",\"doi\":\"10.4103/jrms.jrms_271_23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>In hemodialysis (HD) patients, low serum zinc level could cause hyporesponsivity to erythropoiesis-stimulating agents and lead to anemia. This study investigated the effects of oral zinc supplements on the required dose of erythropoietin in patients undergoing HD.</p><p><strong>Materials and methods: </strong>In a double-blinded randomized trial, 76 HD patients were assigned to 2 groups of 38. One group (intervention) was treated with oral zinc supplements of 210 mg, daily for 6 months, and the other group (control) used placebo capsules for 6 months. The serum zinc level, hemoglobin level, and required dose of erythropoietin, albumin, ferritin, ferrous, and total iron-binding capacity were evaluated 3 and 6 months after intervention.</p><p><strong>Results: </strong>Repeated measures ANOVA did not show a significant increase in Hb level after 6 months of intervention (<i>P</i> = 0.28). However, the required dose of erythropoietin was decreased, but the changes were not statistically significant (<i>P</i> > 0.05). The changes in the other variables were not statistically significant.</p><p><strong>Conclusion: </strong>Oral zinc supplementation in HD patients could not increase hemoglobin level irrespective of their serum zinc level.</p>\",\"PeriodicalId\":50062,\"journal\":{\"name\":\"Journal of Research in Medical Sciences\",\"volume\":\"28 \",\"pages\":\"85\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-02-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10953733/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Research in Medical Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4103/jrms.jrms_271_23\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Research in Medical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/jrms.jrms_271_23","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
The effect of oral zinc on hemoglobin and dose of erythropoietin in hemodialysis patients.
Background: In hemodialysis (HD) patients, low serum zinc level could cause hyporesponsivity to erythropoiesis-stimulating agents and lead to anemia. This study investigated the effects of oral zinc supplements on the required dose of erythropoietin in patients undergoing HD.
Materials and methods: In a double-blinded randomized trial, 76 HD patients were assigned to 2 groups of 38. One group (intervention) was treated with oral zinc supplements of 210 mg, daily for 6 months, and the other group (control) used placebo capsules for 6 months. The serum zinc level, hemoglobin level, and required dose of erythropoietin, albumin, ferritin, ferrous, and total iron-binding capacity were evaluated 3 and 6 months after intervention.
Results: Repeated measures ANOVA did not show a significant increase in Hb level after 6 months of intervention (P = 0.28). However, the required dose of erythropoietin was decreased, but the changes were not statistically significant (P > 0.05). The changes in the other variables were not statistically significant.
Conclusion: Oral zinc supplementation in HD patients could not increase hemoglobin level irrespective of their serum zinc level.
期刊介绍：
Journal of Research in Medical Sciences, a publication of Isfahan University of Medical Sciences, is a peer-reviewed online continuous journal with print on demand compilation of issues published. The journal’s full text is available online at http://www.jmsjournal.net. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
